Discuss SLU-PP-332 on glp1chat
Join the forum to discuss research with other members.
At a glance
SLU-PP-332 is a small molecule used to activate estrogen-related receptors, which help regulate how cells use energy. Animal studies measure changes in fuel use and endurance-related markers. These are not the same receptors as classical estrogen receptors, and the compound is not a peptide.
Estrogen-related receptors are regulators of genes involved in cell energy use, despite their confusing name. SLU-PP-332 activates these regulators in experiments, and animal studies examine changes in fuel use and endurance markers. It is not a form of estrogen and does not act on the usual estrogen receptors. A change in one exercise-like marker is not the same as gaining the broad benefits of physical activity.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source discusses experimental exercise-related metabolic responses. Such findings do not establish that a compound reproduces the broad health effects of exercise in humans.
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of SLU-PP-332.
A comprehensive adverse-effect profile is not established by the source record. Consult the cited studies for what was measured and what remains uncertain.
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg · 1 source tables
Murine-Equivalent Protocol (3 mL = ~1.67 mg/mL)
| Phase | Daily Dose (mcg) | Per-Injection Dose (mcg) | Units per Injection (mL) |
|---|---|---|---|
| Weeks 1–2 | 1250 mcg | 625 mcg | 37.5 units (0.375 mL) |
| Weeks 3–8 | 2500 mcg | 1250 mcg | 75 units (0.75 mL) |
Route & Frequency: Published murine studies used intraperitoneal administration twice daily (25–50 mg/kg)[1][2][3]. Daily mcg values above are expressed for a 25 g mouse. No reputable sources support once-daily subcutaneous use for this compound.
Additional schedule context & duration
Concise summary of the murine-based regimen.
- Evidence Status: Preclinical only—no human trials exist[1][11].
- Mechanism: Pan-ERR agonist; activates aerobic-exercise gene program and enhances mitochondrial function.
- Published Route: Intraperitoneal administration in mice (25–50 mg/kg twice daily).
- Cycle Length: 8 weeks in published studies.
- Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL).
- Storage: Lyophilized frozen; reconstituted refrigerated.
Murine-equivalent dosing framework.
- Initial Phase (Weeks 1–2): 1250 mcg daily (625 mcg per injection, twice daily).
- Maintenance Phase (Weeks 3–8): 2500 mcg daily (1250 mcg per injection, twice daily).
- Frequency: Twice per day, reflecting published murine regimens[1][2][3].
- Route: Intraperitoneal (as studied in preclinical models).
- Timing: Consistent intervals between administrations.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves compound stability[7][8][9][10].
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation.
- Protect from light during storage and handling.
Materials & quantity planning
Source materials checklist · 5 mg
Based on an 8–16 week murine-equivalent protocol with twice-daily administration.
-
Peptide Vials (SLU-PP-332, 5 mg each):
- 8 weeks ≈ 25 vials
- 12 weeks ≈ 39 vials
- 16 weeks ≈ 53 vials
-
Insulin Syringes (U-100):
- Per week: 14 syringes (2/day)
- 8 weeks: 112 syringes
- 12 weeks: 168 syringes
- 16 weeks: 224 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (25 vials): 75 mL → 8 × 10 mL bottles
- 12 weeks (39 vials): 117 mL → 12 × 10 mL bottles
- 16 weeks (53 vials): 159 mL → 16 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each administration.
- Per week: 28 swabs (4/day)
- 8 weeks: 224 swabs → recommend 3 × 100-count boxes
- 12 weeks: 336 swabs → recommend 4 × 100-count boxes
- 16 weeks: 448 swabs → recommend 5 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 5 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
Research publication
Journal of Pharmacology and Experimental Therapeutics (2024) — A Synthetic ERR Agonist Alleviates Metabolic Syndrome (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Public health resource
CDC (2024) — Vaccine Administration: Subcutaneous Injection (Job Aid) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 06
Public health resource
CDC (2024) — Vaccine Administration—Best Practices (Subcutaneous Injections) (opens in a new tab)www.cdc.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.